Maze Therapeutics (MAZE) Revenue (2024 - 2026)

Maze Therapeutics (MAZE) reported Revenue of $20.0 million for Q1 2026, up 113.11% sequentially from -$152.5 million in Q4 2024.

Maze Therapeutics (MAZE) Revenue (2024 - 2026) Analysis & Trends

Maze Therapeutics (MAZE) has 2 years of Revenue data on file, last reported at $20.0 million in Q1 2026.

  • For the quarter ending Q1 2026, Revenue changed N/A year-over-year to $20.0 million; the trailing twelve-month figure through Mar 2026 stood at $20.0 million (up 114.81% YoY), and the FY2024 full-year result was $15.0 million, changed N/A from the prior year.
  • Revenue improved to $20.0 million in Q1 2026, from -$152.5 million in the prior quarter.
  • In the past five years, Revenue ranged from a high of $20.0 million in Q1 2026 to a low of -$152.5 million in Q4 2024.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Revenue (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - -
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn 1.51 Bn
4 NuCana 279.75 Bn 279.75 Bn - -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn 2.99 Bn
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn 3.61 Bn
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn 1.56 Bn
9 Revolution Medicines 37.78 Bn 37.78 Bn - -
10 Maze Therapeutics 1.49 Bn 1.49 Bn 18.21 Mn 20.00 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 20.00 Mn
Dec 31, 2024 -152.50 Mn
Sep 30, 2024 2.50 Mn
Jun 30, 2024 15.00 Mn